@prefix activity: .
@prefix address: .
@prefix agency: .
@prefix assay: .
@prefix assayCategory: .
@prefix assayTargetLink: .
@prefix biopax3: .
@prefix calbc: .
@prefix calbc-group: .
@prefix carrierLink: .
@prefix certainAgreement: .
@prefix chebi: .
@prefix chembl: .
@prefix chemicalCompound: .
@prefix chemicalCompoundRecord: .
@prefix clan: .
@prefix clinicalResult: .
@prefix clinicalStudy: .
@prefix clinicaltrials: .
@prefix company: .
@prefix confidenceScore: .
@prefix contact: .
@prefix country: .
@prefix cpath: .
@prefix curationLookup: .
@prefix dailymed: .
@prefix dailymed-drugs: .
@prefix dailymed-ingredient: .
@prefix dailymed-instance: .
@prefix databaseReference: .
@prefix dc: .
@prefix dc-term: .
@prefix diseaseontology: .
@prefix diseasome: .
@prefix diseasome-diseases: .
@prefix diseasome-gene: .
@prefix diseasome-instance: .
@prefix documentType: .
@prefix dosageForm: .
@prefix drug: .
@prefix drugbank: .
@prefix drugbank-proteinSequence: .
@prefix drugCategory: .
@prefix drugInteraction: .
@prefix drugTarget: .
@prefix eligibility: .
@prefix entrez-gene: .
@prefix entrez-goterm: .
@prefix entrezgene: .
@prefix enzymeLink: .
@prefix externalIdentifier: .
@prefix externalLink: .
@prefix factforge: .
@prefix family: .
@prefix foaf: .
@prefix formulation: .
@prefix freebase: .
@prefix gene-rif: .
@prefix geneontology: .
@prefix geneSequence: .
@prefix hapmap: .
@prefix indication: .
@prefix intervention: .
@prefix investigator: .
@prefix label: .
@prefix lhgdn: .
@prefix lifeskim: .
@prefix linkedct: .
@prefix linkedct-condition: .
@prefix linkedct-intervention: .
@prefix literatureCitation: .
@prefix lld: .
@prefix location: .
@prefix measurement: .
@prefix meddraSideEffect: .
@prefix mixture: .
@prefix molecularSpecies: .
@prefix molecule: .
@prefix moleculeType: .
@prefix ontotext: .
@prefix organismSpecies: .
@prefix outcomeAnalysis: .
@prefix outcomeMeasure: .
@prefix overallOfficial: .
@prefix owl: .
@prefix owlim: .
@prefix packager: .
@prefix participantFlow: .
@prefix patent: .
@prefix pfam: .
@prefix phenotype: .
@prefix pointOfContact: .
@prefix price: .
@prefix primaryOutcome: .
@prefix product: .
@prefix property: .
@prefix proteinSequence: .
@prefix pubmed: .
@prefix pubmed-article: .
@prefix pubmed-author: .
@prefix pubmed-mesh: .
@prefix pubmed-meshheading: .
@prefix pubmed-qualifier: .
@prefix rdf: .
@prefix rdfs: .
@prefix relationshipType: .
@prefix relontology: .
@prefix reportingGroup: .
@prefix researchStem: .
@prefix responsibleParty: .
@prefix result: .
@prefix resultsBaseline: .
@prefix resultsMeasure: .
@prefix resultsOutcome: .
@prefix secondaryOutcome: .
@prefix sideEffect: .
@prefix sideEffectFrequency: .
@prefix sider: .
@prefix sider-drug: .
@prefix skos: .
@prefix skos-xl: .
@prefix snp: .
@prefix structureType: .
@prefix studyMilestone: .
@prefix studyParticipants: .
@prefix studyPeriod: .
@prefix substructure: .
@prefix symptom: .
@prefix synonym: .
@prefix targetLink: .
@prefix targetType: .
@prefix taxonomy: .
@prefix taxonomyClass: .
@prefix taxonomyKingdom: .
@prefix transporterLink: .
@prefix umls: .
@prefix umls-concept: .
@prefix umls-label: .
@prefix umls-semnetwork: .
@prefix uniprot: .
@prefix uniprot-protein: .
@prefix uniprot-unstable: .
@prefix xsd: .
dailymed-drugs:4003 a , dailymed-instance:drugs ;
rdfs:label "Diphenhydramine Hydrochloride (Injection)" ;
dailymed-instance:dosage """THIS PRODUCT IS FOR
INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY. Diphenhydramine
Hydrochloride Injection is indicated when the oral form is impractical. DOSAGE SHOULD BE
INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE
PATIENT.
Pediatric Patients,
Other Than Premature Infants and Neonates: 5 mg/kg/24
hours or 150 mg/m/24 hours. Maximum daily dosage is
300 mg. Divide into four doses, administered intravenously at a
rate generally not exceeding 25 mg/min, or deep
intramuscularly.
Adults: 10 to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or
deep intramuscularly; 100 mg if required; maximum daily dosage
is 400 mg. Parenteral drug products should be
inspected visually for particulate matter and discoloration
prior to administration, whenever solution and container
permit.""" ;
dailymed-instance:description """Diphenhydramine
Hydrochloride Injection is a sterile, nonpyrogenic solution for
intravenous or deep intramuscular use as an antihistaminic agent. Each
mL contains diphenhydramine hydrochloride 50 mg and benzethonium
chloride 100 mcg in Water for Injection. pH 4.0-6.5; sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment. The chemical name
of diphenhydramine hydrochloride is
2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride. The structural
formula is as follows: CHNO���HCl MW 291.82 Diphenhydramine
hydrochloride occurs as a white crystalline powder and is freely soluble
in water and alcohol.""" ;
dailymed-instance:clinicalPharmacology """Diphenhydramine
hydrochloride is an antihistamine with anticholinergic (drying) and
sedative side effects. Antihistamines appear to compete with histamine
for cell receptor sites on effector cells. Diphenhydramine
hydrochloride in the injectable form has a rapid onset of action.
Diphenhydramine is widely distributed throughout the body, including the
CNS. A portion of the drug is excreted unchanged in the urine, while the
rest is metabolized via the liver. Detailed information on the
pharmacokinetics of Diphenhydramine Hydrochloride Injection is not
available.""" ;
dailymed-instance:activeIngredient dailymed-ingredient:diphenhydramine_hydrochloride ;
dailymed-instance:contraindication """Use in Neonates or Premature Infants: This drug
should not be
used in neonates or premature infants.
Use in Nursing
Mothers: Because of
the higher risk of antihistamines for infants generally, and for
neonates and prematures in particular, antihistamine therapy is
contraindicated in nursing mothers.
Use as a Local
Anesthetic: Because of
the risk of local necrosis, this drug should not be used as a
local anesthetic.
Antihistamines are
also Contraindicated in the Following Conditions: Hypersensitivity to diphenhydramine hydrochloride and other
antihistamines of similar chemical structure.""" ;
dailymed-instance:supply """Diphenhydramine
Hydrochloride Injection, USP 50 mg/mL 1 mL DOSETTE vials
packaged in 25s (NDC 0641-0376-25)
Storage: Protect from light. Keep covered in
carton until time of use. Store at 20��-25��C (68��-77��F),
excursions permitted to 15��-30��C (59��-86��F) [see USP
Controlled Room Temperature]. Baxter and
Dosette are trademarks of Baxter International Inc., or its
subsidiaries. Manufactured by Baxter Healthcare
Corporation Deerfield,
IL 60015 USA For Product Inquiry 1 800 ANA DRUG (1-800-262-3784) MLT-43/1.0""" ;
dailymed-instance:activeMoiety dailymed-ingredient:diphenhydramine ;
dailymed-instance:inactiveIngredient dailymed-ingredient:water , dailymed-ingredient:sodium_hydroxide , dailymed-ingredient:hydrochloric_acid , dailymed-ingredient:benzethonium_chloride ;
dailymed-instance:precaution """General: Diphenhydramine hydrochloride has an atropine-like action and,
therefore, should be used with caution in patients with a
history of bronchial asthma, increased intraocular pressure,
hyperthyroidism, cardiovascular disease or hypertension. Use
with caution in patients with lower respiratory disease,
including asthma.
Information for
Patients: Patients
taking diphenhydramine hydrochloride should be advised that this
drug may cause drowsiness and has an additive effect with
alcohol. Patients
should be warned about engaging in activities requiring mental
alertness, such as driving a car or operating appliances,
machinery, etc.
Drug Interactions: Diphenhydramine hydrochloride has additive effects with alcohol
and other CNS depressants (hypnotics, sedatives, tranquilizers,
etc.) MAO
inhibitors prolong and intensify the anticholinergic (drying)
effects of antihistamines.
Carcinogenesis,
Mutagenesis, Impairment of Fertility: Long-term
studies in animals to determine mutagenic and carcinogenic
potential have not been performed.
Pregnancy:
Teratogenic
Effects���Pregnancy Category B: Reproduction studies have been performed in rats and
rabbits at doses up to 5 times the human dose and have
revealed no evidence of impaired fertility or harm to
the fetus due to diphenhydramine hydrochloride. There
are, however, no adequate and well-controlled studies in
pregnant women. Because animal reproduction studies are
not always predictive of human response, this drug
should be used during pregnancy only if clearly
needed.
Pediatric Use: Diphenhydramine should not be used in neonates and premature
infants . Diphenhydramine may diminish mental alertness, or in the young
pediatric patient, cause excitation. Overdosage may cause
hallucinations, convulsions or death . See also
DOSAGE AND ADMINISTRATION section.""" ;
dailymed-instance:overdosage """Antihistamine
overdosage reactions may vary from central nervous system depression to
stimulation. Stimulation is particularly likely in pediatric patients.
Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils;
flushing, and gastrointestinal symptoms may also occur. Stimulants should not be used. Vasopressors may be
used to treat hypotension.""" ;
dailymed-instance:genericMedicine "diphenhydramine hydrochloride" ;
dailymed-instance:fullName "Diphenhydramine Hydrochloride (Injection)" ;
dailymed-instance:adverseReaction """The most frequent
adverse reactions are italicized.
General: Urticaria;
drug rash; anaphylactic shock; photosensitivity; excessive
perspiration; chills; dryness of mouth, nose and
throat.
Cardiovascular
System: Hypotension, headache, palpitations, tachycardia,
extrasystoles.
Hematologic System: Hemolytic
anemia, thrombocytopenia, agranulocytosis.
Nervous System: Sedation, sleepiness, dizziness, disturbed coordination,
fatigue, confusion, restlessness, excitation, nervousness,
tremor, irritability, insomnia, euphoria, paresthesia, blurred
vision, diplopia, vertigo, tinnitus, acute labyrinthitis,
neuritis, convulsions.
Gastrointestinal
System: Epigastric distress, anorexia,
nausea, vomiting, diarrhea, constipation.
Genitourinary
System: Urinary
frequency, difficult urination, urinary retention, early
menses.
Respiratory System: Thickening of bronchial
secretions, tightness of chest and wheezing, nasal
stuffiness.""" ;
dailymed-instance:warning """Antihistamines
should be used with considerable caution in patients with narrow-angle
glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction,
symptomatic prostatic hypertrophy or bladder-neck obstruction. Local necrosis has
been associated with the use of subcutaneous or intradermal use of
intravenous diphenhydramine.
Use in Pediatric
Patients: In
pediatric patients, especially, antihistamines in overdosage may cause
hallucinations, convulsions or death. As in
adults, antihistamines may diminish mental alertness in
pediatric patients. In the young pediatric patient,
particularly, they may produce excitation.
Use in the Elderly
(approximately 60 years or older): Antihistamines are more likely to cause dizziness, sedation and
hypotension in elderly patients.""" ;
dailymed-instance:indication """Diphenhydramine
Hydrochloride Injection is effective in adults and pediatric patients,
other than premature infants and neonates, for the following conditions
when the oral form is impractical:
Antihistaminic: For
amelioration of allergic reactions to blood or plasma, in
anaphylaxis as an adjunct to epinephrine and other standardmeasures after the acute symptoms have been controlled and for
other uncomplicated allergic conditions of the immediate type
when oral therapy is impossible or contraindicated.
Motion Sickness: For active
treatment of motion sickness.
Antiparkinsonism: For use in
parkinsonism, when oral therapy is impossible or
contraindicated, as follows: parkinsonism in the elderly who are
unable to tolerate more potent agents, mild cases of
parkinsonism in other age groups and in other cases of
parkinsonism in combination with centrally acting
anticholinergic agents.""" ;
dailymed-instance:representedOrganization ;
dailymed-instance:routeOfAdministration ;
dailymed-instance:name "Diphenhydramine Hydrochloride" .